Objective: The effectiveness of palonosetron without delayed dexamethasone dosing against emesis was investigated in patients scheduled to receive the corticosteroid-containing combination of doxorubicin and paclitaxel (AT) for 3 cycles. Methods: Chemo-naïve women with breast cancer receiving doxorubicin (60 mg/m2) and paclitaxel (200 mg/m2) were eligible. Patients received palonosetron 0.25 mg intravenously before chemotherapy, however, all patients also received a premedication consisting of prednisone (25 mg orally the evening before therapy) and hydrocortisone (250 mg intravenously just before paclitaxel). The primary end point was complete control (CC; no vomiting, no rescue anti-emetics, and no more than mild nausea) during the overall phase (days 1-5) following cycle 1. Results: Seventy-six patients were enrolled and evaluable (median age 50 years). Fifty-six patients (74%; 95% CI 62-83%) achieved overall CC. Acute (day 1) and delayed (days 2-5) CC rates were 78 and 74%, respectively. No vomiting rates for the acute, delayed and overall phases were 85, 85 and 83%, respectively. An exploratory analysis showed only a small decrease in the probability of achieving CC between cycle 1 (74%) and cycle 3 (66%). Conclusion: The dexamethasone-sparing strategy prevented emesis in more than 70% of breast cancer patients receiving their initial cycle of AT chemotherapy.
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? : Analysis of a phase II trial / S. Damian, L. Celio, E. De Benedictis, P. Mariani, F. Agustoni, F. Ricchini, F. De Braud. - In: ONCOLOGY. - ISSN 0030-2414. - 84:6(2013), pp. 371-377.
|Titolo:||Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? : Analysis of a phase II trial|
DAMIAN, SILVIA (Primo)
RICCHINI, FRANCESCA (Penultimo)
DE BRAUD, FILIPPO GUGLIELMO MARIA (Ultimo)
|Parole Chiave:||combined chemotherapy protocols; breast neoplasms; carcinoma; constipation; dexamethasone; doxorubicin; female; headache; humans; isoquinolines; middle aged; nausea; paclitaxel; quinuclidines; serotonin antagonists; time factors; treatment outcome; vomiting; young adult|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||2013|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1159/000348538|
|Appare nelle tipologie:||01 - Articolo su periodico|